Fulvestrant Injection
NDC Package 68462-317-32

11-digit billing NDC: 68462031732 · Billing unit: ML · 10 ML per package

Package Information

Fulvestrant injection is monotherapyFulvestrant injection is indicated for the treatment of:•Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or•HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.Combination Therapy•Fulvestrant injection is indicated for the treatment of:•HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.•HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. This formulation utilizes a injection delivery system. Marketed by Glenmark Pharmaceuticals Inc., Usa, this product is identified by NDC 68462-317 and is authorized under FDA application ANDA207754.

Identification & Billing

NDC Package Code
68462-317-32
Package Description
2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS (68462-317-40)
Product Code
11-Digit Billing Format
68462031732
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
10 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Fulvestrant
Non-Proprietary Name
Fulvestrant
Substance Name
Fulvestrant
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
Usage Information
MonotherapyFulvestrant injection is indicated for the treatment of:•Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or•HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.Combination Therapy•Fulvestrant injection is indicated for the treatment of:•HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.•HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

Regulatory & Marketing

Labeler Name
Glenmark Pharmaceuticals Inc., Usa
Product Type
Human Prescription Drug
FDA Application #
ANDA207754
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-22-2019
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68462-317-32 identifies a specific commercial package of 2 syringe, glass in 1 carton / 5 ml in 1 syringe, glass (68462-317-40) of Fulvestrant, a human prescription drug labeled by Glenmark Pharmaceuticals Inc., Usa. This product is billed per "ML" milliliter and contains an estimated amount of 10 billable units per package. This injection is formulated for intramuscular use and contains fulvestrant as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glenmark Pharmaceuticals Inc., Usa on August 22, 2019. The current certification is valid through December 31, 2027.

How is this Glenmark Pharmaceuticals Inc., Usa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68462031732. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68462-317-32
11-Digit CMS (5-4-2)
68462-0317-32

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.